Living with moderate to severe asthma can be challenging, with frequent flare-ups making it hard to breathe and enjoy life. A new study is evaluating a drug called brenipatide to see if it can help adults with this condition. The study will last about 65 weeks and will compare different doses of brenipatide to a placebo, which is a treatment that doesn’t contain an active drug. The main goal is to measure how often asthma flare-ups occur over a year of treatment. With an estimated 531 participants, this research could provide valuable insights into a new option for those struggling to control their asthma. If brenipatide proves effective, it might lead to better control of symptoms and improved quality of life for many people.
Could a new drug help people with severe asthma breathe easier?
Plain Language Summary
What this means for you:
Brenipatide is being tested to see if it can reduce asthma flare-ups in adults with severe asthma. What this means for you:
Brenipatide is being tested to see if it can reduce asthma flare-ups in adults with severe asthma. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Asthma
Intervention(s): Brenipatide (DRUG), Brenipatide (DRUG), Placebo (DRUG)
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Primary Outcome(s): Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment
Enrollment: 531 (ESTIMATED)
Lead Sponsor: Eli Lilly and Company
Start: 2025-10-22 | Primary Completion: 2028-04